Following Tf-CRM107 infusion, a ≥50% decrease in tumor volume showed on MRI occurred in nine of the 15 patients who could be evaluated (60%), including one patient having no evidence of tumor on MRI for 23 months after a single infusion of Tf-CRM107 into a progressing recurrent GBM and no tumor cells on the biopsies of the region of treatment at two and 10 months after treatment. The gene discussed is TF; the disease is glioblastoma.